What does the AIMS assessment evaluate?

The AIMS assessment evaluates the severity of abnormal movements, specifically focusing on the presence of tardive dyskinesia and other extrapyramidal symptoms that may arise as a side effect of antipsychotic medications. This assessment is critical for monitoring patients who are on long-term antipsychotic treatment, as it helps clinicians identify the emergence or progression of unwanted movements, which can significantly impact a patient's quality of life.

The AIMS assessment includes a structured examination where the clinician rates various involuntary movements, providing a comprehensive overview of the patient's motor functioning. By systematically assessing these symptoms, healthcare providers can make informed decisions regarding treatment changes, such as dosage adjustments or switching medications, enhancing the overall management of psychiatric conditions. Thus, the primary focus is on the motor side effects related to medication, making it essential for monitoring neurological health in patients treated with antipsychotics.